In today’s session ACADIA Pharmaceuticals Inc. (ACAD) registered an unusually high (500) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious ACAD increase. With 500 contracts traded and 35964 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: ACAD170120C00045000 closed last at: $1.05 or 4.5% down. About 2.13 million shares traded hands. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has risen 16.49% since March 14, 2016 and is uptrending. It has outperformed by 10.87% the S&P500.
Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on November, 3. They expect $-0.60 EPS, down 53.85% or $0.21 from last year’s $-0.39 per share. After $-0.63 actual EPS reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -4.76% EPS growth.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage
Out of 4 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. ACADIA Pharmaceuticals has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was maintained by JP Morgan on Friday, September 4 with “Buy”. The firm has “Hold” rating by Vetr given on Monday, August 10. The firm has “Mkt Perform” rating by Leerink Swann given on Tuesday, October 4. The firm earned “Overweight” rating on Friday, August 7 by Piper Jaffray. Needham maintained it with “Buy” rating and $49 target price in Friday, August 7 report. On Tuesday, May 3 the stock rating was downgraded by Leerink Swann to “Market Perform”. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Outperform” rating given on Sunday, August 9 by Cowen & Co. The rating was upgraded by Piper Jaffray on Friday, January 22 to “Overweight”. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Neutral” rating by Piper Jaffray on Friday, August 7. The firm has “Neutral” rating given on Thursday, August 27 by Piper Jaffray.
According to Zacks Investment Research, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.31, from 1.33 in 2016Q1. The ratio is negative, as 32 funds sold all ACADIA Pharmaceuticals Inc. shares owned while 68 reduced positions. 41 funds bought stakes while 61 increased positions. They now own 104.57 million shares or 4.71% less from 109.74 million shares in 2016Q1.
Riggs Asset Managment Com accumulated 1,300 shares or 0.02% of the stock. Blackrock Fund Advisors has 0.02% invested in the company for 2.34M shares. The Minnesota-based Us Natl Bank De has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Moreover, Raymond James Service has 0.02% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 66,106 shares. Moreover, Point72 Asset Mngmt Ltd Partnership has 0.26% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 1.20M shares. Glob X Company Limited Liability Company holds 244 shares or 0% of its portfolio. Timessquare Capital Llc holds 0.07% or 328,800 shares in its portfolio. Hollencrest Secs Ltd last reported 0.06% of its portfolio in the stock. March Altus Mgmt L P holds 20.75% or 82,723 shares in its portfolio. Raymond James & Assocs holds 8,644 shares or 0% of its portfolio. Alliancebernstein L P has 0% invested in the company for 134,270 shares. Massachusetts Services Ma accumulated 0% or 238,687 shares. Blackrock Invest Management Ltd Limited Liability Company accumulated 35,369 shares or 0% of the stock. Morgan Stanley accumulated 165,740 shares or 0% of the stock. Wells Fargo & Mn, a California-based fund reported 59,584 shares.
Insider Transactions: Since April 18, 2016, the stock had 2 insider buys, and 1 insider sale for $42.47 million net activity. Iversen Leslie L had sold 33,697 shares worth $1.13M on Monday, April 18. $43.00M worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares were bought by BAKER BROS. ADVISORS LP. 1,000 shares were bought by HARRIGAN EDMUND, worth $32,970 on Tuesday, August 16. $560,033 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was sold by Baity Glenn on Monday, July 11.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The company has a market cap of $2.74 billion. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. It currently has negative earnings. The Company’s lead drug candidate, NUPLAZID , is under development for the treatment of Parkinson’s disease psychosis (PDP).
ACAD Company Profile
ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.